Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Fate Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $203.5K in total
- Insiders trading
- 2
- Net value
- −$203.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Fate Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tahl Cindy | See Remarks | 589,355 | Aug 5, 2026 | 5 |
| Valamehr Bahram | President and CEO | 591,815 | Aug 5, 2026 | 4 |
| Redmile Group, LLC | Director, 10% Owner | 12,884,277Indirect | Jun 15, 2026 | 2 |
| Green Jeremy | Director, 10% Owner | 12,884,277Indirect | Jun 15, 2026 | 2 |
| Rastetter William H | Director | 36,331 | Jun 15, 2026 | 2 |
| Epstein Robert S | Director | 36,331 | Jun 15, 2026 | 2 |
| Abernethy Matt | Director | – | Jun 15, 2026 | 1 |
| Agarwal Shefali | Director | 10,490 | Jun 15, 2026 | 1 |
| Lee Michael Stewart | Director | 11,331 | Jun 15, 2026 | 1 |
| Hamill Laura | Director | – | Jun 15, 2026 | 1 |
| Jooss Karin | Director | 9,848 | Jun 15, 2026 | 1 |
| Xu Yuan | Director | 8,669 | Jun 15, 2026 | 1 |
| RedCo II Master Fund, L.P. | Director, 10% Owner | 12,884,277Indirect | Apr 23, 2026 | 1 |
| Adawi Kamal | Chief Financial Officer | 100,000 | Jan 16, 2026 | 2 |
| Mendlein John | Director | 311,231 | May 30, 2025 | 0 |
| Mozaffarian Neelufar | Director | – | May 30, 2025 | 0 |
| Bressi Jerome Charles | See Remarks | 335,203 | Jan 16, 2025 | 0 |
| Coughlin Timothy | Director | 9,892 | Jun 11, 2024 | 0 |
| Dulac Edward J III | Chief Financial Officer | 101,479 | Mar 5, 2024 | 0 |
| Wolchko J Scott | President and CEO | 371,248 | Feb 2, 2024 | 0 |
| Powl Brian T. | Chief Commercial Officer | 41,146 | Jul 6, 2023 | 0 |
| Hershberg Robert | Director | 10,659 | Jun 7, 2023 | 0 |
| Chu Yu-Waye | Chief Medical Officer | 140,676 | Apr 19, 2023 | 0 |
| Plavsic Mark | Chief Technical Officer | 123,705 | Jan 11, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2022 (view filing) | Jun 3 | 3 days | Coughlin TimothyDirector | SSale | −1.44K | $22.81 | −$32.8K | −2.4%57.6K after | |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | Tahl CindyGeneral Counsel and Secretary | SSale | −25.0K | $22.96 | −$574.0K | −11.7%189.2K after | |
| Apr 25, 2022 (view filing) | Apr 21-22 | 4 days | Wolchko J ScottPresident and CEO | SSale | −40.0K | $34.89 | −$1.40M | −8.5%431.5K after | 6 lots |
| Apr 21, 2022 (view filing) | Apr 19 | 2 days | Chu Yu-WayeChief Medical Officer | SSale | −4.06K | $35.37 | −$143.7K | −2.6%151.0K after | |
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Tahl CindyGeneral Counsel and Secretary | SSale | −25.0K | $38.85 | −$971.3K | −11.7%189.2K after | |
| Mar 15, 2022 (view filing) | Mar 14 | 1 day | Valamehr BahramChief R&D Officer | SSale | −25.0K | $31.07 | −$776.7K | −12.2%179.8K after | 5 lots |
| Mar 11, 2022 (view filing) | Mar 10 | 1 day | Mendlein JohnDirector | SSale | −31.6K | $35.02 | −$1.11M | −16.5%159.5K after | 2 lots |
| Jan 24, 2022 (view filing) | Jan 20-21 | 4 days | Wolchko J ScottPresident and CEO | SSale | −40.0K | $39.66 | −$1.59M | −8.5%431.5K after | From original2 lots |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Wolchko J ScottPresident and CEO | SSale | −14.6K | $48.68 | −$709.0K | −3.3%431.5K after | 2 lots |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Tahl CindyGeneral Counsel and Secretary | SSale | −5.42K | $48.53 | −$263.0K | −3.4%155.8K after | 2 lots |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Valamehr BahramChief R&D Officer | SSale | −4.57K | $48.50 | −$221.7K | −3.0%146.5K after | 2 lots |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Dulac Edward J IIIChief Financial Officer | SSale | −1.77K | $48.45 | −$85.8K | −1.6%108.6K after | 2 lots |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Chu Yu-WayeSenior VP Clinical Development | SSale | −3.96K | $48.51 | −$192.3K | −3.2%121.8K after | 2 lots |
| Jan 12, 2022 (view filing) | Jan 10 | 2 days | Wolchko J ScottPresident and CEO | SSale | −34.2K | $46.86 | −$1.60M | −7.1%446.1K after | 3 lots |
| Jan 12, 2022 (view filing) | Jan 10 | 2 days | Tahl CindyGeneral Counsel and Secretary | SSale | −7.74K | $46.43 | −$359.3K | −4.6%161.3K after | 2 lots |
| Jan 12, 2022 (view filing) | Jan 10 | 2 days | Valamehr BahramChief R&D Officer | SSale | −5.60K | $46.38 | −$259.6K | −3.6%151.1K after | 2 lots |
| Jan 4, 2022 (view filing) | Jan 3 | 1 day | Tahl CindyGeneral Counsel and Secretary | SSale | −50.0K | $59.34 | −$2.97M | −22.8%169.0K after | 4 lots |
| Dec 21, 2021 (view filing) | Dec 20 | 1 day | Dulac Edward J IIIChief Financial Officer | SSale | −16.0K | $60.00 | −$958.6K | −12.6%110.4K after | |
| Dec 14, 2021 (view filing) | Dec 13 | 1 day | Valamehr BahramChief R&D Officer | SSale | −25.0K | $47.66 | −$1.19M | −13.8%156.7K after | 5 lots |
| Dec 13, 2021 (view filing) | Dec 10 | 3 days | Chu Yu-WayeSenior VP Clinical Development | SSale | −7.50K | $51.46 | −$385.9K | −5.6%125.8K after | 7 lots |
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Wolchko J ScottPresident and CEO | SSale | −20.0K | $54.27 | −$1.09M | −4.8%393.8K after | |
| Oct 25, 2021 (view filing) | Oct 21-22 | 4 days | Wolchko J ScottPresident and CEO | SSale | −60.0K | $59.55 | −$3.57M | −13.2%393.8K after | 3 lots |
| Oct 4, 2021 (view filing) | Oct 1 | 3 days | Tahl CindyGeneral Counsel and Secretary | SSale | −50.0K | $58.83 | −$2.94M | −31.6%108.0K after | 3 lots |
| Sep 30, 2021 (view filing) | Sep 28 | 2 days | Dulac Edward J IIIChief Financial Officer | SSale | −19.5K | $62.53 | −$1.22M | −27.1%52.4K after | |
| Sep 14, 2021 (view filing) | Sep 13 | 1 day | Valamehr BahramChief Development Officer | SSale | −25.0K | $66.29 | −$1.66M | −20.7%95.7K after | 3 lots |
| Aug 20, 2021 (view filing) | Aug 19 | 1 day | Wolchko J ScottPresident and CEO | SSale | −20.0K | $88.01 | −$1.76M | −4.8%393.8K after | |
| Aug 20, 2021 (view filing) | Aug 19 | 1 day | Dulac Edward J IIIChief Financial Officer | SSale | −3.47K | $88.26 | −$306.6K | −6.0%54.5K after | 3 lots |
| Jul 26, 2021 (view filing) | Jul 22-23 | 4 days | Wolchko J ScottPresident and CEO | SSale | −60.0K | $85.66 | −$5.14M | −13.2%393.8K after | 4 lots |
| Jul 2, 2021 (view filing) | Jul 1 | 1 day | Tahl CindyGeneral Counsel and Secretary | SSale | −55.5K | $85.24 | −$4.73M | −33.9%108.0K after | From original11 lots |